Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Edwin Choy; Karla Ballman; James Chen; Mark A. Dickson; Rashmi Chugh; Suzanne George; Scott Okuno; Raphael Pollock; Rajiv M. Patel; Antje Hoering; Shreyaskumar Patel

doi:10.1155/2019/7608743

Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Edwin Choy, Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh, Suzanne George, Scott Okuno, Raphael Pollock, Rajiv M. Patel, Antje Hoering, Shreyaskumar Patel

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

Original language	English (US)
Article number	7608743
Journal	Sarcoma
Volume	2019
DOIs	https://doi.org/10.1155/2019/7608743
State	Published - 2019

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1155/2019/7608743

Fingerprint

Dive into the research topics of 'Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)'. Together they form a unique fingerprint.

Cite this

Choy, E., Ballman, K., Chen, J., Dickson, M. A., Chugh, R., George, S., Okuno, S., Pollock, R., Patel, R. M., Hoering, A., & Patel, S. (2019). Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517). Sarcoma, 2019, Article 7608743. https://doi.org/10.1155/2019/7608743

Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517). / Choy, Edwin; Ballman, Karla; Chen, James et al.
In: Sarcoma, Vol. 2019, 7608743, 2019.

Research output: Contribution to journal › Comment/debate › peer-review

Choy, E, Ballman, K, Chen, J, Dickson, MA, Chugh, R, George, S, Okuno, S, Pollock, R, Patel, RM, Hoering, A & Patel, S 2019, 'Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)', Sarcoma, vol. 2019, 7608743. https://doi.org/10.1155/2019/7608743

Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S et al. Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517). Sarcoma. 2019;2019:7608743. doi: 10.1155/2019/7608743

@article{a10712b9f4fe40f7a9572ec647bd7ab1,

title = "Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)",

abstract = "In the article titled {"}SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy{"} [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.",

author = "Edwin Choy and Karla Ballman and James Chen and Dickson, {Mark A.} and Rashmi Chugh and Suzanne George and Scott Okuno and Raphael Pollock and Patel, {Rajiv M.} and Antje Hoering and Shreyaskumar Patel",

note = "Publisher Copyright: {\textcopyright} 2019 Edwin Choy et al.",

year = "2019",

doi = "10.1155/2019/7608743",

language = "English (US)",

volume = "2019",

journal = "Sarcoma",

issn = "1357-714X",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Corrigendum

T2 - sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

AU - Choy, Edwin

AU - Ballman, Karla

AU - Chen, James

AU - Dickson, Mark A.

AU - Chugh, Rashmi

AU - George, Suzanne

AU - Okuno, Scott

AU - Pollock, Raphael

AU - Patel, Rajiv M.

AU - Hoering, Antje

AU - Patel, Shreyaskumar

PY - 2019

Y1 - 2019

N2 - In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

AB - In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

UR - http://www.scopus.com/inward/record.url?scp=85072381260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072381260&partnerID=8YFLogxK

U2 - 10.1155/2019/7608743

DO - 10.1155/2019/7608743

M3 - Comment/debate

AN - SCOPUS:85072381260

SN - 1357-714X

VL - 2019

JO - Sarcoma

JF - Sarcoma

M1 - 7608743

ER -

Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this